Myeloid-derived suppressor cells: Natural regulators for transplant tolerance

Human Immunology

Volumn 71, Issue 11, 2010, Pages 1061-1066

  Boros, Peter ^a   Ochando, Jordi C ^a   Chen, Shu Hsia ^a   Bromberg, Jonathan S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Myeloid derived suppressor cells; Organ transplantation; Tolerance

Indexed keywords

ADOPTIVE TRANSFER; BONE MARROW CELL; CANCER PATIENT; CELL ACTIVATION; CELL EXPANSION; HUMAN; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; ORGAN TRANSPLANTATION; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SUPPRESSOR CELL;

ANIMALS; GRAFT REJECTION; HUMANS; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; IMMUNOTHERAPY; MYELOID CELLS; NEOPLASMS; ORGAN TRANSPLANTATION; TRANSPLANTATION TOLERANCE; TUMOR ESCAPE;

EID: 77957754785     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2010.08.001     Document Type: Review

References (80)

1. Yamamoto Y., Ishigaki H., Ishida H., Itoh Y., Noda Y., Ogasawara K. Analysis of splenic Gr-1int immature myeloid cells in tumor-bearing mice. Microbiol Immunol 2008, 52:47-53.
2. Nagaraj S., Gabrilovich D.I. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 2008, 68:2561-2563.
3. Marigo I., Dolcetti L., Serafini P., Zanovello P., Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008, 222:162-179.
4. + T cells. J Clin Invest 2006, 116:2777-2790.
5. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006, 66:1123-1131.
6. Diaz-Montero C.M., Salem M.L., Nishimura M.I., Garrett-Mayer E., Cole D.J., Montero A.J. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009, 58:49-59. iaz-montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ.
7. Bronte V. Therapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol 2009, 9:470-481.
8. Ko J.S., Bukowski R.M., Fincke J.H. Myeloid-derived suppressor cells: a novel therapeutic target. Curr Oncol Rep 2009, 11:87-93.
9. Goni O., Alcaide P., Fresno M. Immunosuppression during acute Trypanosoma cruzi infection: involvement of Ly6G (Gr1(+))CD11b(+)immature myeloid suppressor cells. Int Immunol 2002, 10:1125-1134.
10. Giordanengo L., Guiñazú N., Stempin C., Fretes R., Cerbán F., Gea S. Cruzipain, a major Trypanosoma cruzi antigen, conditions the host immune response in favor of parasite. Eur J Immunol 2002, 2:1003-1011.
11. Voisin M.B., Buzoni-Gatel D., Bout D., Velge-Roussel F. Both expansion of regulatory; GR1+ CD11b+ myeloid cells and anergy of T lymphocytes participate in hyporesponsiveness of the lung-associated immune system during acute toxoplasmosis. Infect Immun 2004, 72:5487-5492.
12. Mencacci A., Montagnoli C., Bacci A., Cenci E., Pitzurra L., Spreca A., et al. CD80+Gr-1+ myeloid cells inhibit development of antifungal Th1 immunity in mice with candidiasis. J Immunol 2002, 169:3180-3190.
13. Kerr E.C., Raveney B.J., Copland D.A., Dick A.D., Nicholson L.B. Analysis of retinal cellular infiltrate in experimental autoimmune uveoretinitis reveals multiple regulatory cell populations. J Autoimmun 2008, 31:354-361.
14. Nicholson L.B., Raveney B.J., Munder M. Monocyte dependent regulation of autoimmune inflammation. Curr Mol Med 2009, 9:23-29.
15. Haile L.A., von Wasielewski R., Gamrekelashvili J., Krüger C., Bachmann O., Westendorf A.M., et al. Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. Gastroenterology 2008, 135:871-881.
16. Llopiz D., Dotor J., Casares N., Bezunartea J., Díaz-Valdés N., Ruiz M., et al. Peptide inhibitors of transforming growth factor-beta enhance the efficacy of antitumor immunotherapy. Int J Cancer 2009, 125:2614-2623.
17. Pan P.Y., Wang G.X., Yin B., Ozao J., Ku T., Divino C.M., Chen S.H. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 2008, 111:219-228.
18. Sinha P., Clements V.K., Fulton A.M., Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007, 67:4507-4513.
19. Serafini P., Carbley R., Noonan K.A., Tan G., Bronte V., Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004, 64:6337-6343.
20. Gabrilovich D., Ishida T., Oyama T., Ran S., Kravtsov V., Nadaf S., et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998, 92:4150-4166.
21. Nefedova Y., Nagaraj S., Rosenbauer A., Muro-Cacho C., Sebti S.M., Gabrilovich D.I. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the Janus-activated kinase. 2/signal transducers and activators of transcription 3 pathway. Cancer Res 2005, 65:9525-9535.
22. Kortylewski M., Kujawski M., Wang T., Wei S., Zhang S., Pilon-Thomas S., et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005, 11:1314-1321.
23. Foell D., Wittkowski H., Vogl T., Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007, 81:28-37.
24. Sinha P., Okoro C., Foell D., Freeze H.H., Ostrand-Rosenberg S., Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol 2008, 181:4666-4675.
25. Li Q., Pan P.Y., Gu P., Xu D., Chen S.H. Role of immature myeloid Gr-1+ cells in the development of antitumor immunity. Cancer Res 2004, 64:1130-1139.
26. Rossner S., Voigtlander C., Wiethe C., Hanig J., Seifarth C., Lutz M.B. Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro. Eur J Immunol 2005, 35:3533-3544.
27. Umemura N., Saio M., Suwa T., Kitoh Y., Bai J., Nonaka K., et al. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol 2008, 83:1136-1144.
28. Pan P.Y., Ma G., Weber K.J., Ozao-Choy J., Wang G., Yin B., et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 2010, 70:99-108.
29. Youn J.I., Nagaraj S., Collazo M., Gabrilovich D.I. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008, 181:5791-5802.
30. Dolcetti L., Peranzoni E., Ugel S., Marigo I., Fernandez Gomez A., Mesa C., et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol 2010, 40:22-35.
31. Geissmann F., Manz M.G., Jung S., Sieweke M.H., Merad M., Ley K. Development of monocytes, macrophages, and dendritic cells. Science 2010, 327:656-661.
32. Peranzoni E., Zilio S., Marigo I., Dolcetti L., Zanovello P., Mandruzzato S., Bronte V. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 2010, 22:238-244.
33. Haile L.A., Gamrekelashvili J., Manns M.P., Korangy F., Greten T.F. CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice. J Immunol 2010, 185:203-210.
34. Hoechst B., Ormandy L.A., Ballmaier M., Lehner F., Krüger C., Manns M.P., et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces;CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008, 135:234-243.
35. Filipazzi P., Valenti R., Huber V., Pilla L., Canese P., Iero M., et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007, 25:2546-2553.
36. Mandruzzato S., Solito S., Falisi E., Francescato S., Chiarion-Sileni V., Mocellin S., et al. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol 2009, 182:6562-6568.
37. Ko J.S., Zea A.H., Rini B.I., Ireland J.L., Elson P., Cohen P., et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009, 15:2148-2157.
38. Schmielau J., Finn O.J. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 2001, 61:4756-4760.
39. Zea A.H., Rodriguez P.C., Atkins M.B., Hernandez C., Signoretti S., Zabaleta J., et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005, 65:3044-3048.
40. Rodriguez P.C., Ernstoff M.S., Hernandez C., Atkins M., Zabaleta J., Sierra R., Ochoa A.C. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009, 69:1553-1560.
41. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9:162-174.
42. Kusmartsev S., Nagaraj S., Gabrilovich D.I. Tumor-associated;CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol 2005, 175:4583-4592.
43. Rutschman R., Lang R., Hesse M., Ihle J.N., Wynn T.A., Murray P.J. Cutting edge: Stat6-dependent substrate depletion regulates nitric oxide production. J Immunol 2001, 166:2173-2177.
44. Sinha P., Clements V.K., Ostrand-Rosenberg S. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res 2005, 65:11743-11751.
45. Terabe M., Matsui S., Park J.M., Mamura M., Noben-Trauth N., Donaldson D.D., et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: Abrogation prevents tumor recurrence. J Exp Med 2003, 198:1741-1752.
46. Delano M.J., Scumpia P.O., Weinstein J.S., Coco D., Nagaraj S., Kelly-Scumpia K.M., et al. MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med 2007, 204:1463-1474.
47. Rodríguez P.C., Ochoa A.C. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: Mechanisms and therapeutic perspectives. Immunol Rev 2008, 222:180-191.
48. Rodriguez P.C., Quiceno D.G., Ochoa A.C. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 2007, 109:1568-1573.
49. Serafini P., Meckel K., Kelso M., Noonan K., Califano J., Koch W., et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006, 203:2691-2702.
50. Szuster-Ciesielska A., Hryciuk-Umer E., Stepulak A., Kupisz K., Kandefer-Szerszeń M. Reactive oxygen species production by blood neutrophils of patients with laryngeal carcinoma and antioxidative enzyme activity in their blood. Acta Oncol 2004, 43:252-258.
51. Sauer H., Wartenberg M., Hescheler J. Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol Biochem 2001, 11:173-186.
52. Dairou J., Dupret J.M., Rodrigues-Lima F. Impairment of the activity of the xenobiotic-metabolizing enzymes arylamine N-acetyltransferases 1 and 2 (NAT1/NAT2) by peroxynitrite in mouse skeletal muscle cells. FEBS Lett 2005, 579:4719-4723.
53. +T cell tolerance in cancer. Nat Med 2007, 13:828-835.
54. Dietlin T.A., Hofman F.M., Lund B.T., Gilmore W., Stohlman S.A., van der Veen R.C. Mycobacteria-induced Gr-1+ subsets from distinct myeloid lineages have opposite effects on T cell expansion. J Leukoc Biol 2007, 81:1205-1212.
55. Movahedi K., Guilliams M., Van den Bossche J., Van den Bergh R., Gysemans C., Beschin A., et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008, 111:4233-4244.
56. + myeloid cells. Cancer Res 2006, 66:6807-6815.
57. Li H., Han Y., Guo Q., Zhang M., Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta. 1. J Immunol 2009, 182:240-249.
58. Liu C., Yu S., Kappes J., Wang J., Grizzle W.E., Zinn K.R. Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood 2007, 109:4336-4342.
59. Dugast A.S., Haudebourg T., Coulon F., Heslan M., Haspot F., Poirier N., Vuillefroy de Silly R., et al. Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion. J Immunol 2008, 180:7898-7906.
60. Dugast A.S., Vanhove B. Immune regulation by non-lymphoid cells in transplantation. Clin Exp Immunol 2009, 156:25-34.
61. De Wilde V., Van Rompaey N., Hill M., Lebrun J.F., Lemaître P., Lhommé F., et al. Endotoxin-induced myeloid-derived suppressor cells inhibit alloimmune responses via heme oxygenase-1. Am J Transplant 2009, 9:2034-2047.
62. Greifenberg V., Ribechini E., Rössner S., Lutz M.B. Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. Eur J Immunol 2009, 39:2865-2876.
63. +Gr1+ myeloid-derived suppressor cells that promote long-term survival of allografts. Transplantation 2008, 86:1125-1134.
64. MacDonald K.P., Rowe V., Clouston A.D., Welply J.K., Kuns R.D., Ferrara J.L., et al. Cytokine expanded myeloid precursors function as regulatory antigen-presenting cells and promote tolerance through IL-10-producing regulatory T cells. J Immunol 2005, 174:1841-1850.
65. Zhou Z., French D.L., Ma G., Eisenstein S., Chen Y., Divino C.M., et al. Development and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells. Stem Cells 2010, 28:620-632.
66. Rodriguez Garcia M., Ledgerwood L., Yang Y., Xu J., Lal G., Burrell B., et al. Monocytic suppressive cells mediate transplantation tolerance in mice. J Clin Invest 2010, 120:2486-2496.
67. Chalmin F., Ladoire S., Mignot G., Vincent J., Bruchard M., Remy-Martin J.P., et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest 2010, 120:457-471.
68. Le H.K., Graham L., Cha E., Morales J.K., Manjili M.H., Bear H.D. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol 2009, 9:900-909.
69. Vincent J., Mignot G., Chalmin F., Ladoire S., Bruchard M., Chevriaux A., et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010, 70:3052-3061.
70. Priceman S.J., Sung J.L., Shaposhnik Z., Burton J.B., Torres-Collado A.X., Moughon D.L., et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood 2010, 115:1461-1471.
71. Nefedova Y., Fishman M., Sherman S., Wang X., Beg A.A., Gabrilovich D.I. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res 2007, 67:11021-11028.
72. Lathers DM, Clark JI, Achille NJ, Young MR. Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin;D3. Cancer Immunol Immunother 53:422-30.
73. Walkley C.R., Yuan Y.D., Chandraratna R.A., McArthur G.A. Retinoic acid receptor antagonism in vivo expands the numbers of precursor cells during granulopoiesis. Leukemia 2002, 16:1763-1772.
74. Ochando J.C., Homma C., Yang Y., Hidalgo A., Garin A., Tacke F., et al. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol 2006, 7:652-662.
75. Judge T.A., Wu Z., Zheng X.G., Sharpe A.H., Sayegh M.H., Turka L.A. The role of CD80;CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. J Immunol 1999, 162:1947-1951.
76. Aharoni R., Yussim A., Sela M., Arnon R. Combined treatment of glatiramer acetate and low doses of immunosuppressive drugs is effective in the prevention of graft rejection. Int Immunopharmacol 2005, 5:23-32.
77. West K. CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Curr Opin Investig Drugs 2009, 10:491-504.
78. Ozao-Choy J., Ma G., Kao J., Wang G.X., Meseck M., Sung M., et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009, 69:2514-2522.
79. Finke J.H., Rini B., Ireland J., Rayman P., Richmond A., Golshayan A., et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008, 14:6674-6682.
80. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009, 9:798-809.